EXTENDED REPORT

Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham Heart Study

Ida K Haugen,1 Vasan S Ramachandran,2,3 Devyani Misra,4 Tuhina Neogi,4 Jingbo Niu,4 Tianzhong Yang,4 Yuqing Zhang,4 David T Felson4

ABSTRACT

Objectives To study whether hand osteoarthritis (OA) is associated with increased mortality and cardiovascular events in a large community-based cohort (Framingham Heart Study) in which OA, mortality and cardiovascular events have been carefully assessed.

Methods We examined whether symptomatic (≥1 joint with radiographic OA and pain in the same joint) and radiographic hand OA (≥1 joint(s) with radiographic OA without pain) were associated with mortality and incident cardiovascular events (coronary heart disease, congestive heart failure and/or atherothrombotic brain infarction) using Cox proportional hazards models. In the adjusted models, we included possible confounding factors from baseline (eg, metabolic factors, medication use, smoking/alcohol). We also adjusted for the number of painful joints in the lower limb and physical inactivity.

Results We evaluated 1348 participants (53.8% women) with mean (SD) age of 62.2 (8.2) years, of whom 540 (40.1%) and 186 (13.8%) had radiographic and symptomatic hand OA, respectively. There was no association between hand OA and mortality. Although there was no significant relation to incident cardiovascular events overall or a relation of radiographic hand OA with events, we found a significant association between symptomatic hand OA and incident coronary heart disease (myocardial infarction/coronary insufficiency syndrome) (HR 2.26, 95% CI 1.22 to 4.18). The association remained after additional adjustment for pain in the lower limb or physical inactivity.

Conclusions Symptomatic hand OA, but not radiographic hand OA, was associated with an increased risk of coronary heart disease events. The results suggest an effect of pain, which may be a possible marker of inflammation.

INTRODUCTION

While the morbidity of osteoarthritis (OA) has been well characterised, we have limited knowledge of OA-related mortality. A recent review showed moderate evidence for an association between OA and mortality, especially for cardiovascular and gastrointestinal mortality.1 Some but not all studies included adjustment for potential confounding factors.

As cardiovascular disease remains the most common cause of mortality, any reduced survival in OA may be related to a greater risk of cardiovascular events. However, few studies have explored the possible association between OA and cardiovascular disease.2–7 Whereas some studies have suggested an association of hand OA with mortality, cardiovascular mortality or cardiovascular biomarkers, the findings within each study and across studies are inconsistent.2–6 Further, as different types of cardiovascular events may have different aetiologies, it would be valuable to explore whether OA is related to specific types of events. We are not aware of previous explorations of this question.

There may be shared risk factors that are associated with both OA and cardiovascular diseases, including immobilisation, metabolic factors, treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or OA-related inflammation.1–10 Unlike knee and hip OA, hand OA is not likely leading to immobilisation, and increased mortality and cardiovascular events may therefore to a larger extent be related to metabolic factors or inflammation. One report suggested a stronger association with imaging biomarkers of cardiovascular disease in those with hand OA compared with those with OA-related knee/hip replacements.11 Alternatively, there may be direct associations between OA and vascular changes.12–13

Hence our aim was to investigate whether participants with hand OA have increased mortality and a greater incidence of cardiovascular events in a community-based cohort under continuous surveillance for disease and mortality events, and to explore potential explanations for the observed associations.

METHODS

Participants
We included in the study participants from the Framingham Heart Study (Original and Offspring cohorts), aged 50–75 years, with available radiographs and information about joint pain enabling classification of hand OA, and data on mortality and cardiovascular events.

In the Original cohort, 5209 men and women, aged 30–62 years, from Framingham, Massachusetts, without overt symptoms of cardiovascular disease or previous heart attack or stroke, were examined in 1948–1953. Participants have been examined every second year up to 2008–2011 (examination cycle 31). At examination cycle 22 (1990–1994), the participants were examined for hand OA.

In the Offspring cohort, 5124 men and women, constituting the children of participants in the Original cohort and the spouses of these children,
were examined in 1971–1975. They have been followed every fourth year (except for 8 years between examination cycle 1 and 2) up to 2011–present (examination cycle 9). At examination cycles 5 (1991–1995) and 7 (1998–2001), participants (whose parents were previously studied for OA) and their spouses were examined for hand OA.

Boston University Medical Center’s institutional review board approved both studies, and written informed consent was obtained.

Assessment of OA and joint pain
Bilateral posteroanterior hand radiographs were obtained at examination cycle 22 (Original cohort), and at examination cycles 5 and 7 (Offspring cohort). Radiographs were read by one of two academically based musculoskeletal radiologists (BS, PA). Bilateral 2nd–5th distal and proximal interphalangeal, thumb interphalangeal, 1st–5th metacarpophalangeal and thumb base (carpometacarpal/scaphotrapezial joint) were graded for OA (30 joints) using a modified Kellgren–Lawrence Scale.

If the participants answered ‘yes’ to the question “On most days, do you have any pain, aching or stiffness in any of your joints?”, they were shown a homunculus and asked to indicate which joint(s) had complaints. We calculated the number of painful joints (range 0–8) in the lower limb, including the bilateral hips, knees, ankles and feet (five toes counted as one joint). The Framingham Physical Activity Index (PAI) was completed at examination cycles 20 (Original cohort) and 4 (Offspring cohort). Participants were divided into tertiles based on their PAI scores.

We were especially interested in symptomatic hand OA as these participants are more likely to seek medical care. To avoid having participants with non-symptomatic radiographic hand OA in our reference group, we divided participants into three categories based on their hand OA status at examination cycles 22 (Original cohort) and 5 (Offspring cohort); (1) symptomatic hand OA, (2) radiographic hand OA and (3) no symptomatic/radiographic hand OA. Symptomatic hand OA was defined as ≥1 joint(s) with radiographic hand OA (Kellgren–Lawrence grade ≥2) and pain/aching/stiffness in the same joint(s) (30 joints assessed). Radiographic hand OA was defined as ≥1 joint(s) with radiographic OA (Kellgren–Lawrence grade ≥2) without pain/aching/stiffness in the same joint(s) (30 joints assessed).

Assessment of mortality, cardiovascular events and comorbidities
Participants were carefully followed for occurrence of cardiovascular events and death through hospital admission records, death certificates, death registries, medical records and periodic examinations. The diagnoses were arrived at by a panel of cardiologists and neurologists using published criteria. We had available data on mortality and cardiovascular events at year end 2009 and 2011, respectively.

Mortality
Overall mortality included mortality related to cardiovascular events, cancer and unknown/unspecified causes.

Cardiovascular events
Incident cardiovascular events included incident coronary heart disease (coronary insufficiency syndrome/myocardial infarction), congestive heart failure and/or atherothrombotic brain infarction (table 1).

Covariates
Body mass index (BMI), elevated blood glucose, lipid profile, hypertension, previous self-reported cancer, medications (lipid lowering treatment, antihypertensives, antidiabetics, NSAIDs and aspirin) and alcohol were assessed at examination cycles 22 (Original cohort) and 5 (Offspring cohort). As covariates, we also included self-reported smoking status at examination cycles 17–22 (Original cohort) and 1–5 (Offspring cohort) in order to capture previous smoking. Previous cardiovascular events had been adjudicated by a panel of physicians (table 1).

Statistical analyses
We calculated mortality/morbidity rates (95% CI) per 1000 person-years. We determined the number of person-years in the analyses by adding the years from assessment of hand OA (examination cycles 22 and 5 for the Original and Offspring cohorts, respectively) until event of interest/death or censoring for all participants.

We examined whether symptomatic/radiographic hand OA were associated with mortality and incident cardiovascular events using Cox proportional hazards models (IBM SPSS Statistics V20, SAS V9.2). Participants with previous events of interest were excluded from the analyses. Analyses were adjusted for age, sex, cohort, body mass index, comorbidities and lifestyle factors. We also performed analyses with additional adjustment for the number of painful joints in the lower limb and tertiles of the PAI score. In the main analyses, those with incident hand OA at examination cycle 7 were characterised as no OA (based on examination cycle 5 status). We repeated the analyses excluding participants with incident hand OA at examination cycle 7 from the no OA group (n=244), and also carried out analyses using age as the primary time scale. Appropriateness of the multivariable models was checked by testing the assumption of proportionality of hazards.

To explore possible dose–response relationships, we examined whether bilateral OA showed stronger associations than unilateral OA, and whether the associations got stronger with increasing number of affected joints and with increasing Kellgren–Lawrence sum score.

We excluded participants below 50 or above 75 years of age. Those below 50 years had few events and the majority had no hand OA. Among those over 75 years of age, hand OA was almost universal (see online supplementary table S1).

RESULTS
In the Original cohort, 5209 participants were enrolled at examination cycle 1, of whom 1166 (22.4%) attended examination cycle 22. Hand OA status at examination cycle 22 was available for 985 participants, and 276 met our inclusion criteria (figure 1). In the Offspring cohort, 5124 participants were enrolled at examination cycle 1, of whom 3799 (74.1%) and 3539 (69.1%) attended examination cycles 5 and 7, respectively. Hand OA status at examination cycle 5 was available for 1709 participants, and 1072 met our inclusion criteria (figure 1).

Participants with hand OA were older and there was a higher proportion of women. Further, previous cancer, hypertension, elevated blood glucose, use of antihypertensives, antidiabetic treatment, NSAIDs and aspirin were more frequent in participants with hand OA (table 2).

Mortality
We observed 454 deaths, of which 243 and 75 occurred in participants with radiographic and symptomatic hand OA.
Cardiovascular events

Among those with no previous cardiovascular events, 242 incident events were observed, of which 122 and 48 occurred in participants with radiographic and symptomatic hand OA, respectively. Incident coronary heart disease (n=117) and congestive heart failure (n=155) occurred more frequently than participants with radiographic and symptomatic hand OA (table 3). There was a trend, although not statistically significant in multivariable analyses, towards an association between symptomatic hand OA and cardiovascular events (table 4). However, a statistically significant association was found between symptomatic hand OA and coronary heart disease, whereas the association was borderline statistically significant for radiographic hand OA (table 4). Male sex, age, antidiabetic treatment and smoking were also associated with coronary heart disease (smoking borderline statistically significant) (data not shown). When we excluded Offspring participants with incident hand OA at examination cycle 7 from the analyses (figure 1), we found similar results (table 5). No significant associations were found between hand OA and congestive heart failure or atherothrombotic stroke (tables 4 and 5). Similar results were found when using age as the primary time scale (data not shown).

Cardiovascular events

- Mortality related to cardiovascular events, cancer and mortality due to unknown/unspecified causes
- History of ≥15 min chest pain accompanied by transient ischaemic changes in the ECG, but without changes in serum biomarkers of myocardial necrosis
- ≥2 of 3 findings; (1) typical symptoms, (2) changes in serum biomarkers and/or (3) ECG indicating myocardial infarction. Autopsy showing new/recent MI was also accepted as evidence
- Minimum of two major or one major and two minor criteria present concurrently
- Sudden/rapid onset of focal neurological deficits>24 h without known sources of embolism, intracranial haemorrhage, known hypercoagulable states or other disease processes causing focal neurological deficits
- Weight (kg) and height (m) measured after standardised procedures
- Non-fasting glucose of ≥200 mg/dL (≥11.1 mmol/L) or fasting glucose of ≥126 mg/dL (≥ 7.0 mmol/L)
- Elevated blood pressure (systolic ≥160 mmHg and/or diastolic ≥95 mmHg) measured by two physicians
- Previous coronary insufficiency syndrome, MI, CHF and atherothrombotic stroke, as described above (ie, the diagnoses were arrived at by a panel of cardiologists and neurologists)
- Previous cancer reported by the patient in a clinical interview
- Current use of insulin and oral hypoglycaemics assessed in a clinical interview
- Current use of non-steroidal anti-inflammatory agents (Motrin, ibuprofen, Indocin, Clinoril) assessed in a clinical interview
- Daily use of aspirin (≥6 days per week) assessed in a clinical interview
- Alcohol consumption (yes/no) assessed in a clinical interview
- Regularly smoking of cigarettes the last year and smoking of cigars and pipes assessed in a clinical interview (examination cycles 1–5 for Offspring and examination cycles 17–22 for Original cohort)

Table 1: Detailed description of outcomes of interest and covariates in the analyses

<table>
<thead>
<tr>
<th>Mortality</th>
<th>Cardiovascular events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall mortality</td>
<td>Coronary insufficiency syndrome</td>
</tr>
<tr>
<td>Mortality related to cardiovascular events, cancer and mortality due to unknown/unspecified causes</td>
<td>History of ≥15 min chest pain accompanied by transient ischaemic changes in the ECG, but without changes in serum biomarkers of myocardial necrosis</td>
</tr>
<tr>
<td>Recent/acute myocardial infarction (MI)</td>
<td>≥2 of 3 findings; (1) typical symptoms, (2) changes in serum biomarkers and/or (3) ECG indicating myocardial infarction. Autopsy showing new/recent MI was also accepted as evidence</td>
</tr>
<tr>
<td>Congestive heart failure (CHF)</td>
<td>Minimum of two major or one major and two minor criteria present concurrently</td>
</tr>
<tr>
<td>Atherothrombotic brain infarction</td>
<td>Sudden/rapid onset of focal neurological deficits&gt;24 h without known sources of embolism, intracranial haemorrhage, known hypercoagulable states or other disease processes causing focal neurological deficits</td>
</tr>
</tbody>
</table>

respectively. Deaths per 1000 person-years were higher in participants with hand OA (table 3). However, those with hand OA were older than hand OA free participants. In the adjusted analyses (in which age was the main confounder), there was no significant association between hand OA and mortality (table 4). Male sex, age, elevated blood glucose, antihypertensive treatment, smoking and cancer and previous cardiovascular events were associated with higher mortality, whereas alcohol was associated with lower mortality (data not shown). When we excluded Offspring participants with incident hand OA at examination cycle 7 from our reference group (figure 1), we found a statistically significant lower risk of mortality associated with hand OA (table 5). Similar results in adjusted analyses were found using age as the primary time scale (data not shown).
signiﬁcant association between symptomatic hand OA and coronary heart disease (data not shown). We found similar trends of associations to coronary heart disease in those below 50 years, but not above 75 years (see online supplementary table S1).

The validity of the multivariable models in table 4 was found to be satisfactory (data not shown).

DISCUSSION

In the community based study of Framingham, hand OA was not associated with increased mortality. However, participants with symptomatic hand OA were more likely to experience coronary heart disease.

We had the advantage of a long follow-up period, assessment of survival status and a thorough clinical examination, allowing us to study the association to mortality with adjustment for possible confounding/mediating factors. In adjusted analyses, we found a trend towards reduced mortality associated with hand OA (table 4), in contrast with a previous study by Nüesch et al investigating mortality in participants with knee/hip OA. Contrasting findings may be due to different study designs. Participants in the study by Nüesch et al were selected from general practices in the UK, and only those with pain were invited for a clinical examination and knee/hip radiography. Mortality of the study participants was compared against mortality of the general population. In the Framingham Study, both participants with and without OA were recruited from the general population, limiting the risk of selection bias. There may also be differences in mortality between participants with OA in the lower limb and hand OA, although the diseases may overlap. We did not investigate cardiovascular mortality.
separately as we have the impression that this is a specific but not a sensitive outcome in the Framingham Study. Specifically, in case of sudden death, participants were classified with ‘unknown cause’, although cardiovascular causes were most likely. We therefore used cardiovascular events instead of cardiovascular death as the outcome of interest.

Previous studies have shown associations between hand OA and imaging markers of atherosclerosis, which was confirmed with imaging markers of atherosclerosis, which was confirmed.

Table 2 Baseline characteristics of participants included in the study

<table>
<thead>
<tr>
<th>Overall (n=1348)</th>
<th>Hand OA status</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) (mean (SD))</td>
<td>62.2 (8.2)</td>
<td>57.6 (6.4)</td>
</tr>
<tr>
<td>Sex (n (%)) female</td>
<td>725 (53.8)</td>
<td>303 (47.8)</td>
</tr>
<tr>
<td>BMI (kg/m²) (mean (SD))</td>
<td>27.6 (4.6)</td>
<td>27.4 (4.5)</td>
</tr>
<tr>
<td>No of symptomatic hand OA joints (median (IQR)) (range 0–30)</td>
<td>0 (0, 0)</td>
<td>0 (0, 0)</td>
</tr>
<tr>
<td>No of joints with radiographic OA (range 0–30)</td>
<td>1 (0, 5)</td>
<td>0 (0, 0)</td>
</tr>
<tr>
<td>No of painful finger joints (range 0–30)</td>
<td>0 (0, 1)</td>
<td>0 (0, 0)</td>
</tr>
<tr>
<td>No of painful joints in lower limb (median (IQR)) (range 0–8)</td>
<td>0 (0, 2)</td>
<td>0 (0, 2)</td>
</tr>
</tbody>
</table>

Comorbidities and risk factors

Increased blood pressure (n (%)) | 98 (7.3) | 31 (5.0) | 48 (8.9) | 19 (10.2) |
Total cholesterol/HDL ratio, mean (SD) | 4.6 (1.5) | 4.6 (1.6) | 4.5 (1.4) | 4.5 (1.4) |
Increased fasting/non-fasting blood glucose (n (%)) | 101 (7.5) | 38 (6.1) | 49 (9.1) | 14 (7.7) |
Self-reported previous cancer (n (%)) | 282 (21.0) | 114 (18.3) | 120 (22.4) | 48 (26.1) |
Smoking (current/previous) (n (%)) | 605 (44.9) | 316 (50.8) | 219 (40.6) | 70 (37.6) |
Alcohol consumption (n (%)) | 887 (65.7) | 425 (68.4) | 343 (63.5) | 119 (64.0) |
Low physical activity (n (%)) | 414 (32.3) | 177 (30.7) | 174 (31.6) | 63 (31.7) |

Previous events (before examination cycle 22 in the Original cohort and before examination cycle 5 in the Offspring cohort)

Cardiovascular events (n (%)) | 92 (6.8) | 37 (5.9) | 40 (7.4) | 5 (8.1) |
Coronary heart disease (n (%)) | 75 (5.6) | 31 (5.0) | 32 (5.9) | 12 (6.5) |
Congestive heart failure (n (%)) | 19 (1.4) | 5 (0.8) | 10 (1.9) | 4 (2.2) |
Atherothrombotic brain infarction (n (%)) | 13 (1.0) | 6 (1.0) | 5 (0.9) | 2 (1.1) |

Medication

Current antihypertensive treatment (n (%)) | 371 (27.7) | 129 (19.8) | 174 (33.3) | 70 (38.3) |
Current lipid lowering treatment (n (%)) | 139 (10.3) | 59 (9.5) | 53 (9.8) | 27 (14.5) |
Current anti-diabetic treatment (oral/insulin) (n (%)) | 52 (3.9) | 16 (2.6) | 25 (4.6) | 11 (5.9) |
Current NSAIDs (n (%)) | 163 (12.1) | 66 (10.6) | 62 (11.5) | 35 (18.8) |
Daily aspirin (n (%)) | 258 (19.4) | 87 (14.1) | 126 (23.6) | 45 (24.5) |

BMI, body mass index; HDL, high density lipoprotein; NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis.

Table 3 Deaths and events per 1000 person-years

<table>
<thead>
<tr>
<th>Overall (n=1348)</th>
<th>Hand OA status</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No hand OA (n=622)</td>
<td>Radiographic hand OA (n=540)</td>
<td>Symptomatic hand OA (n=186)</td>
</tr>
<tr>
<td>Survival time (time to death or censoring) (years) (median (IQR))</td>
<td>16.0 (14.4, 16.9)</td>
<td>16.2 (14.8, 17.0)</td>
</tr>
<tr>
<td>Deaths per 1000 person-years (95% CI)</td>
<td>23 (21, 25)</td>
<td>14 (12, 17)</td>
</tr>
<tr>
<td>Overall deaths</td>
<td>6 (5, 7)</td>
<td>3 (2, 5)</td>
</tr>
<tr>
<td>Cardiovascular deaths (coronary heart disease, cerebrovascular accidents, other)</td>
<td>7 (6, 8)</td>
<td>6 (4, 8)</td>
</tr>
<tr>
<td>Deaths due to cancer</td>
<td>10 (9, 11)</td>
<td>5 (4, 6)</td>
</tr>
<tr>
<td>Events in those with no previous events per 1000 person-years (95% CI)</td>
<td>14 (12, 16)</td>
<td>8 (6, 10)</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td>6 (5, 8)</td>
<td>4 (3, 5)</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>8 (7, 9)</td>
<td>4 (3, 6)</td>
</tr>
<tr>
<td>Atherothrombotic brain infarction</td>
<td>3 (2, 4)</td>
<td>2 (1, 3)</td>
</tr>
</tbody>
</table>

OA, osteoarthritis.
Several studies have demonstrated an association between symptomatic hand OA and coronary heart disease. However, the observed association remained statistically significant after adjustment for several metabolic factors and the use of NSAIDs (table 4). Whether the association is mediated through other markers of atherosclerosis nor significant for OA in other finger joints. NSAIDs are commonly used as pain management for OA and have been associated with cardiovascular disease. A recent systematic review concluded that OA was not associated with C reactive protein serving as a proxy for systemic inflammation, but they did not specifically evaluate symptomatic hand OA. OA finger joints with pain may exhibit more synovitis than non-painful joints although the systemic effect is not yet known.

As hand OA is often a marker of generalised OA, the observed association between symptomatic hand OA and coronary heart disease could have been due to a more sedentary lifestyle associated with knee/hip OA. Nüesch et al found that

### Table 4

| HR (95% CI) of mortality and cardiovascular events in participants with radiographic and symptomatic hand osteoarthritis compared with those with no hand osteoarthritis as reference |
|---------------------------------|---------------------------------|---------------------------------|
| Mortality                       | Crude model                     | Adjusted model 1*               | Adjusted model 2†               |
| No hand OA                      | 1.0 (ref)                       | 1.0 (ref)                       | 1.0 (ref)                       |
| Radiographic hand OA            | 2.32 (1.88–2.86); p<0.001       | 0.79 (0.61–1.01); p=0.06        | 0.82 (0.63–1.07); p=0.14        |
| Symptomatic hand OA             | 2.07 (1.56–2.75); p<0.001       | 0.75 (0.55–1.03); p=0.08        | 0.79 (0.57–1.10); p=0.16        |

EVENTS (in participants with no previous events of interest)

| Cardiovascular events           | Crude model                     | Adjusted model 1*               | Adjusted model 2†               |
| No hand OA                      | 1.0 (ref)                       | 1.0 (ref)                       | 1.0 (ref)                       |
| Radiographic hand OA            | 2.25 (1.68–3.02); p<0.001       | 1.04 (0.74–1.46); p=0.83        | 1.02 (0.72–1.45); p=0.90        |
| Symptomatic hand OA             | 2.59 (1.80–3.73); p<0.001       | 1.25 (0.83–1.89); p=0.28        | 1.32 (0.87–2.03); p=0.19        |

| Coronary heart disease          | Crude model                     | Adjusted model 1*               | Adjusted model 2†               |
| No hand OA                      | 1.0 (ref)                       | 1.0 (ref)                       | 1.0 (ref)                       |
| Radiographic hand OA            | 2.19 (1.44–3.34); p<0.001       | 1.44 (0.89–2.35); p=0.14        | 1.60 (0.96–2.66); p=0.07        |
| Symptomatic hand OA             | 2.56 (1.52–4.32); p<0.001       | 1.89 (1.04–3.41); p=0.04        | 2.26 (1.22–4.18); p=0.009       |

| Congestive heart failure        | Crude model                     | Adjusted model 1*               | Adjusted model 2†               |
| No hand OA                      | 1.0 (ref)                       | 1.0 (ref)                       | 1.0 (ref)                       |
| Radiographic hand OA            | 2.66 (1.82–3.89); p<0.001       | 0.92 (0.59–1.44); p=0.72        | 0.89 (0.56–1.41); p=0.63        |
| Symptomatic hand OA             | 3.25 (2.06–5.14); p<0.001       | 1.18 (0.71–1.98); p=0.52        | 1.23 (0.71–2.13); p=0.45        |

| Atherothrombotic stroke         | Crude model                     | Adjusted model 1*               | Adjusted model 2†               |
| No hand OA                      | 1.0 (ref)                       | 1.0 (ref)                       | 1.0 (ref)                       |
| Radiographic hand OA            | 1.84 (1.03–3.30); p=0.04        | 0.82 (0.43–1.58); p=0.56        | 0.73 (0.37–1.42); p=0.36        |
| Symptomatic hand OA             | 2.28 (1.11–4.71); p<0.03        | 1.04 (0.47–2.31); p=0.91        | 0.99 (0.44–2.26); p=0.99        |

*Adjusted for age, sex, cohort and BMI.
†Adjusted for age, sex, cohort, BMI, total cholesterol/HDL ratio, current lipid lowering treatment, increased blood pressure, current antihypertensive treatment, elevated fasting or non-fasting blood glucose, current antidiabetic treatment (oral or insulin), previous cardiovascular events (coronary heart disease, congestive heart failure, atherothrombotic stroke), previous cancer, current use of NSAIDs, daily use of aspirin, current/previous smoking, alcohol use.
‡Adjusted for age, sex, cohort, BMI, total cholesterol/HDL ratio, current lipid lowering treatment, increased blood pressure, current antihypertensive treatment, elevated fasting or non-fasting blood glucose, current antidiabetic treatment (oral or insulin), current use of NSAIDs, daily use of aspirin, current/previous smoking, alcohol use.

BMI, body mass index; HDL, high density lipoprotein; NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis.
walking disability was a major risk factor for mortality in patients with knee/hip OA, supporting this hypothesis. However, in the current study, neither pain in the lower limb nor low physical activity levels could explain the observed association between symptomatic hand OA and coronary heart disease, rather suggesting the importance of metabolic/systemic factors. These findings, which may provide important insights into shared disease mechanisms, need confirmation in other investigations.

We can only speculate why we observed an association between symptomatic hand OA and coronary heart disease on the one hand, but a trend towards lower mortality on the other. One reason may be the use of overall mortality as the outcome and not cardiovascular mortality specifically. Hence other diseases causing death such as cancer may drive the association to reduced overall mortality. Although this was not the aim of the study, we found an association between hand OA and reduced cancer-related mortality, which was statistically significant for radiographic hand OA and borderline statistically significant for symptomatic hand OA (data not shown).

Some limitations are worth mentioning. Even though there was no evidence for a dose dependent relationship (ie, number of OA joints, total OA score and bilateral vs unilateral disease), we showed that participants with symptomatic hand OA had a higher risk of coronary heart disease than those with radiographic (non-symptomatic) hand OA (table 4). We believe that hand OA severity does not necessarily depend on the number of joints affected. Symptomatic hand OA may represent a more severe stage than non-symptomatic hand OA, giving us some support for a dose dependent relationship. The PAI score was not completed at the examination cycle on which hand OA was diagnosed. Due to the explorative study design, we did not adjust for multiple testing. However, using the Bonferroni method, the association between symptomatic hand OA and coronary heart disease would remain statistically significant.

In conclusion, we found that symptomatic hand OA was associated with more coronary heart disease events. However, the link behind the observed association is not completely understood. Additional studies are needed to confirm these findings. Established risk factors for coronary heart disease, such as unfavourable metabolic profile, NSAIDs, pain in the lower limb or low physical activity, could not fully explain the observed association.

Acknowledgements We wish to thank Piran Aliabadi and Burton Sack for reading the hand radiographs, and the study participants for their willingness to participate in the study.

Contributors IKH: study design, analyses, interpretation of the data, drafting the article and final approval. VSR and DM: study design, critical revision of the article and final approval. TN, YZ and DTF: study design, interpretation of the data, critical revision of the article and final approval. VSR and DM: study design, critical revision of the article and final approval. TN, YZ and DTF: study design, interpretation of the data, critical revision of the article and final approval. TN and YZ: analyses, critical revision of the article and final approval.

Funding Supported by NIH AR47785 and HL-NO-025195 (NHLBI). IKH received funding from South-Eastern Norway Regional Health Authority, Anders Jahre's fund and Nathalia and Knut Juul Christiansen's foundation.

Competing interests None.

Ethics approval Boston University Medical Center's institutional review board approved the studies.

Provenance and peer review Not commissioned; externally peer reviewed.

### Table 5 HR (95% CI) of mortality and cardiovascular events in those with radiographic and symptomatic hand osteoarthritis compared with those without hand osteoarthritis

<table>
<thead>
<tr>
<th>Events (in participants with no previous events of interest)</th>
<th>Crude model</th>
<th>Adjusted model 1*</th>
<th>Adjusted model 2†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular events</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No hand OA</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Radiographic hand OA</td>
<td>1.53 (1.22–1.90); p&lt;0.001</td>
<td>0.58 (0.45–0.74); p&lt;0.001</td>
<td>0.62 (0.48–0.81); p&lt;0.001</td>
</tr>
<tr>
<td>Symptomatic hand OA</td>
<td>1.36 (1.02–1.82); p=0.04</td>
<td>0.55 (0.40–0.76); p&lt;0.001</td>
<td>0.60 (0.43–0.84); p=0.003</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No hand OA</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Radiographic hand OA</td>
<td>2.12 (1.42–3.16); p&lt;0.001</td>
<td>1.01 (0.65–1.58); p=0.95</td>
<td>1.08 (0.68–1.71); p=0.76</td>
</tr>
<tr>
<td>Symptomatic hand OA</td>
<td>2.36 (1.31–4.24); p&lt;0.001</td>
<td>1.69 (0.88–3.25); p=0.12</td>
<td>1.98 (1.00–3.89); p=0.05</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No hand OA</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Radiographic hand OA</td>
<td>2.02 (1.23–3.33); p&lt;0.001</td>
<td>1.31 (0.75–2.29); p=0.24</td>
<td>1.42 (0.79–2.52); p=0.24</td>
</tr>
<tr>
<td>Symptomatic hand OA</td>
<td>2.36 (1.31–4.24); p&lt;0.001</td>
<td>1.69 (0.88–3.25); p=0.12</td>
<td>1.98 (1.00–3.89); p=0.05</td>
</tr>
<tr>
<td>Atherothrombotic stroke</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No hand OA</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Radiographic hand OA</td>
<td>2.29 (1.47–3.56); p&lt;0.001</td>
<td>0.88 (0.54–1.44); p=0.61</td>
<td>0.85 (0.51–1.42); p=0.54</td>
</tr>
<tr>
<td>Symptomatic hand OA</td>
<td>2.79 (1.67–4.65); p&lt;0.001</td>
<td>1.12 (0.63–1.96); p=0.70</td>
<td>1.16 (0.64–2.09); p=0.63</td>
</tr>
</tbody>
</table>

*Adjusted for age, sex, cohort and BMI.
†Adjusted for age, sex, cohort, BMI, total cholesterol/HDL ratio, current lipid lowering treatment, increased blood pressure, current antihypertensive treatment, elevated fasting or non-fasting blood glucose, current anti-diabetic treatment (oral or insulin), previous cardiovascular events (coronary heart disease, congestive heart failure, atherothrombotic stroke), previous cancer, current use of NSAIDs, daily use of aspirin, current/previous smoking, alcohol use.
‡Adjusted for age, sex, cohort, BMI, total cholesterol/HDL ratio, current lipid lowering treatment, increased blood pressure, current antihypertensive treatment, elevated fasting or non-fasting blood glucose, current anti-diabetic treatment (oral or insulin), current use of NSAIDs, daily use of aspirin, current/previous smoking, alcohol use. BMI: body mass index; HDL: high density lipoprotein; NSAIDs: non-steroidal anti-inflammatory drugs; OA: osteoarthritis.
REFERENCES

Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham Heart Study

Ida K Haugen, Vasan S Ramachandran, Devyani Misra, Tuhina Neogi, Jingbo Niu, Tianzhong Yang, Yuqing Zhang and David T Felson

Ann Rheum Dis 2015 74: 74-81 originally published online September 18, 2013
doi: 10.1136/annrheumdis-2013-203789

Updated information and services can be found at:
http://ard.bmj.com/content/74/1/74

These include:

Supplementary Material
Supplementary material can be found at:
http://ard.bmj.com/content/suppl/2013/09/18/annrheumdis-2013-203789.DC1

References
This article cites 36 articles, 13 of which you can access for free at:
http://ard.bmj.com/content/74/1/74#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Epidemiology (1395)
- Pain (neurology) (883)
- Degenerative joint disease (4641)
- Musculoskeletal syndromes (4951)
- Osteoarthritis (931)
- Immunology (including allergy) (5144)
- Inflammation (1251)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/